-
Mashup Score: 0Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer - 3 year(s) ago
The objective of this study is to externally validate the KELIM (rate of elimination of CA-125 elimation) score in patients with high grade serous ovarian cancer(HGSC)undergoing NACT and determine its relation to outcome of cytoreduction, platinum sensitivity, progression free(PFS) and overall survival(OS).
Source: Gynecologic OncologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis - 3 year(s) ago
The value of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC) is controversial and its use remains experimental in most national and international guidelines. We wished to systematically evaluate all available evidence.
Source: Gynecologic OncologyCategories: Hematologists1, Latest HeadlinesTweet-
Value of HIPEC appears to depend on the timing of the last systemic chemotherapy exposure-metaanalysis shows if the gap is >6 months no benefit in PFS or OS https://t.co/X5p0qCbLl9
-
-
Mashup Score: 0CRABP2 – A novel biomarker for high-risk endometrial cancer - 3 year(s) ago
Investigate the clinical and functional implications of elevated CRABP2 expression in endometrial cancer (EC) patients.
Source: Gynecologic OncologyCategories: Hematologists1, Latest HeadlinesTweet-
CRABP2 – a novel biomarker for high-risk endometrial cancer- high expression is associated with advanced stage, high grade, and reduced overall survival https://t.co/UGNK03ocDu
-
-
Mashup Score: 1Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy - 3 year(s) ago
The risk of financial toxicity from cancer care is rising as the rapidly growing cancer patient population suffers from more costly, albeit more personalized and advanced, cancer treatments; this burden is disproportionately felt in vulnerable populations [1]. As commonly understood, financial toxicity involves three domains of hardship: material (financial losses due to out-of-pocket expenses…
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to talk to @gynoncjnls EIC @David_Cohn_MD and author @JCohenMD on this podcast about #FinancialToxicity in #gyncsm and discuss what WE can do to improve affordability for our patients. 📰https://t.co/hUBGYBG3Xn 📰https://t.co/7E6L44XLvq 🎙️https://t.co/PjGNtD16kz
-
Happy to talk to @gynoncjnls EIC @David_Cohn_MD and author @JCohenMD on this podcast about #FinancialToxicity in #gyncsm and discuss what WE can do to improve affordability for our patients. 📰https://t.co/hUBGYBG3Xn 📰https://t.co/7E6L44XLvq 🎙️https://t.co/PjGNtD16kz
-
-
Mashup Score: 0
The Laparoscopic Approach to Cervical Cancer (LACC) trial found that minimally invasive radical hysterectomy compared to open radical hysterectomy compromised oncologic outcomes and was associated with worse progression-free survival (PFS) and overall survival (OS) in early-stage cervical carcinoma. We sought to assess oncologic outcomes at multiple centers between minimally invasive (MIS)…
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
The surgical approach for cervical cancer is not yet answered. Await the multiple RCTs ongoing round the world but for now enjoy. https://t.co/W5m8sOd6Y1
-
-
Mashup Score: 6Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy - 3 year(s) ago
The risk of financial toxicity from cancer care is rising as the rapidly growing cancer patient population suffers from more costly, albeit more personalized and advanced, cancer treatments; this burden is disproportionately felt in vulnerable populations [1]. As commonly understood, financial toxicity involves three domains of hardship: material (financial losses due to out-of-pocket expenses…
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Important editorial from @EmelineAvikiMD @fumikochino et al. on financial toxicity of surgical treatment of gynaecological cancers. Also thank you for the shout out to the #cancergroundshot philosophy. https://t.co/OklnxszHfA https://t.co/TlRhiSzQp2
-
-
Mashup Score: 1Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial - 3 year(s) ago
Progression-free survival (PFS) is an important early efficacy endpoint in ovarian cancer (OC) and its relevance to patients should be assessed. PRIMA, a phase III trial, assessed niraparib in patients with OC; this post hoc analysis examined the relationship between disease progression in OC and health-related quality of life (HRQoL).
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @omalleygynonc: https://t.co/BQjWr9syTL In ovarian cancer: "Disease progression negatively impacted HRQoL... PFS is clinically relevant…
-
-
Mashup Score: 1Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification - 3 year(s) ago
We measured the variation in practice across all aspects of endometrial cancer (EC) management and assessed the potential impact of implementation of molecular classification.
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@David_Cohn_MD #EditorsChoice in the May @gynoncjnls is a great one. time to really make this change. congrats to authors https://t.co/dbtORnzKqF #endometrial cancer @SGO_org #progress https://t.co/FsX3x1YIBC
-
-
Mashup Score: 2Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake - 3 year(s) ago
To determine the feasibility of hospital-based genetic counseling and testing (GC/T) Traceback for Ovarian Cancer (OC) patients, as proposed by the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute.
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
We can (and must) do better to engage patients and their families in #genetic counseling/testing for hereditary cancer syndromes. Prevention is key to reducing the #cancer burden! https://t.co/3MJb2txwXN @NOCC_National @GeneticCouns
-
-
Mashup Score: 2Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States - 3 year(s) ago
Given that cervical cancer incidence rates do not decline in women >65, there is generally limited screening, and these women have a poor prognosis, it is imperative to better understand this population. We aim to describe the characteristics, treatment, and survival of women >65 diagnosed with cervical cancer.
Source: Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Study: Most patients with #CervicalCancer past age of routine screening are diagnosed with locally advanced or metastatic disease #GynecologicOncology #GCSM https://t.co/2xPhPSa9xn
-
KELIM score is a marker of chemosensitivity in patients with ovarian cancer treated with NACT- KELIM<1 likely to have platinum-resistant disease and worse PFS and OS https://t.co/3Ytmo36JOe